386 filings
Page 7 of 20
8-K
73f1ccl3t8oob4m1gwh
12 Nov 21
Motus GI Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:07am
8-K
gdenaydzg
26 Oct 21
Motus GI Announces Presentation of Results from Independent Study of Pure-Vu System in IBP Patients at the 2021 ACG Annual Scientific Meeting
8:12am
8-K
prxrl 5hla06g54
8 Sep 21
Motus GI Announces Enrollment of Patients at Second Site in the European Union
8:16am
8-K
pumq0brc65bv2bpodsy
27 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
t74oxrmur 4d0gu044
12 Aug 21
Motus GI Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
pqwcm q4dz9oq
21 Jul 21
Motus GI Secures Expanded $12M Credit Financing to Support Growth Strategy
8:06am
DEFA14A
nm4e4tw
2 Jul 21
Additional proxy soliciting materials
4:17pm
4
k7wg6r
23 Jun 21
Motus GI / Sonja Nelson ownership change
4:13pm
3
xz8b5r56yllh 3n3cah
23 Jun 21
Motus GI / Sonja Nelson ownership change
4:11pm
8-K
lhau3iq9pdvzyjk
23 Jun 21
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
4:10pm
8-K
f8i ch90m
16 Jun 21
Motus GI Announces First Patients Enrolled in the European Union Feasibility Study
8:05am
8-K
jowiwv0x
3 Jun 21
Motus GI Announces Publication of Pure-Vu® System Clinical Data
8:11am
8-K
5myg9cevdf p5xk656sd
25 May 21
Implementation of the Pure-Vu System is designed to improve efficiencies and outcomes
8:05am
8-K
4t2yaycmys
13 May 21
Motus GI Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
ke864yhj
7 May 21
Motus GI Announces Publication of a Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource Allocation
7:37am